Tabata Tsutomu
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
Article types | Original article |
Language | English |
Peer review | Peer reviewed |
Title | The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG. |
Journal | Formal name:Journal of gynecologic oncology Abbreviation:J Gynecol Oncol ISSN code:20050399/20050380 |
Domestic / Foregin | Foregin |
Volume, Issue, Page | 31(6),pp.e94 |
Author and coauthor | Kondo Eiji, Tabata Tsutomu, Suzuki Nao, Aoki Daisuke, Yahata Hideaki, Kotera Yoshio, Tokuyama Osamu, Fujiwara Keiichi, Kimura Eizo, Terauchi Fumitoshi, Sumi Toshiyuki, Okamoto Aikou, Yaegashi Nobuo, Enomoto Takayuki, Sugiyama Toru |
Authorship | 2nd author |
Publication date | 2020/11 |
Summary | OBJECTIVE:In this study we sought to investigate the clinical factors that affect post-progression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC). We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC.METHODS:We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC.RESULTS:A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30-2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC.CONCLUSIONS:Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as well as other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population. |
DOI | 10.3802/jgo.2020.31.e94 |
PMID | 33078599 |